Good things come in 3s: New publications arising from EU funded collaborations on biomarker research and discovery

We are pleased to have been involved in this trio of papers examining biomarkers and genetic modifiers in Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). These studies were based on collaborative work under the BIO-NMD project led led by Alessandra Ferlini and funded by the European Union’s Seventh Framework Program from 2010-2012. Biomarkers are characteristics that can be used to monitor disease progression, response to treatment, and prognosis, while genetic modifiers are genes that can affect the expression of other genes and influence the phenotype of a patient. The discovery of biomarkers and genetic modifiers allows for more personalized treatments and advice to patients. While the publication of these papers may have taken longer than the funding duration, this does demonstrate the ability of research projects to have long-term impact many years following the conclusion of a project.

Capitanio et al., 2020 Showed mechanosensing and metabolic dysfunction as central features of BMD and DMD, with DMD demonstrating further dysregulation in extracellular matrix composition.

Is available open access on the Journal of Cachexia, Sarcopenia and Muscle website.

Spitali et al., 2020 demonstrated that variants in TCTEX1D1 on chromosome 1 were associated with age of ambulation loss.

Is available open access on the European Journal of Human Genetics website.

Signorelli et al., 2019 revealed that serum levels of MDH2 correlated with disease stage and response to treatment with corticosteroids; furthermore, they were associated with the risk of wheelchair dependency and pulmonary function.

Is available open access on the Journal of Cachexia, Sarcopenia and Muscle website.


Read next...


On #RareDiseaseDay, ENMC launches white paper for shared decision making in NMD research

Two years ago, the European Neuromuscular Centre (ENMC) held a special meeting to explore the position of neuromuscular patients in Shared-Decision-Making (SDM) and develop recommendations....

New pan-Canadian neuromuscular network unites doctors, researchers and patients for better research and care

Network lead Dr Hanns Lochmüller In case you missed it! Exciting news for Canadian NMD networking. We're excited to share news...

Walk for Muscular Dystrophy Announce Dates and Times Across Canada

Muscular Dystrophy Canada (MDC) have announced the dates and times of their annual Walk for Muscular Dystrophy in more than 40 locations across Canada. Funds...

New Publication: COL4A1-related autosomal recessive encephalopathy in 2 Turkish children

We are happy to have been involved with this paper presenting the neurological phenotypes of 2 Turkish brothers with a novel mutation. Through whole-exome sequencing...

New Publication: Activities of daily living in myotonic dystrophy type 1

Our new paper on activities of daily living in patients with myotonic dystrophy type 1 (DM1) is now available online at Acta Neurologica Scandinavica. We...

New publication: De novo variant in SCN4A causes neonatal sodium channel myotonia with general muscle stiffness and respiratory failure

We were pleased to collaborate with colleagues  in Germany on this case report describing a de novo variant in SCN4A resulting in a phenotype of...